Assertio Holdings, Inc. (NASDAQ:ASRT) Shares Sold by Perritt Capital Management Inc

Perritt Capital Management Inc lowered its stake in shares of Assertio Holdings, Inc. (NASDAQ:ASRT) by 4.4% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 372,899 shares of the company’s stock after selling 17,250 shares during the period. Perritt Capital Management Inc owned about 0.39% of Assertio worth $325,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in ASRT. Geode Capital Management LLC boosted its stake in shares of Assertio by 2.0% during the 4th quarter. Geode Capital Management LLC now owns 1,095,911 shares of the company’s stock worth $955,000 after acquiring an additional 21,059 shares in the last quarter. Commonwealth Equity Services LLC purchased a new stake in Assertio during the fourth quarter worth $30,000. Wealthfront Advisers LLC acquired a new stake in Assertio in the fourth quarter valued at $53,000. CM Management LLC grew its holdings in Assertio by 23.1% in the fourth quarter. CM Management LLC now owns 400,000 shares of the company’s stock valued at $348,000 after purchasing an additional 75,000 shares during the last quarter. Finally, Palumbo Wealth Management LLC raised its stake in shares of Assertio by 10.6% during the 4th quarter. Palumbo Wealth Management LLC now owns 205,598 shares of the company’s stock worth $179,000 after buying an additional 19,637 shares during the last quarter. 48.96% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

ASRT has been the topic of a number of research reports. StockNews.com cut shares of Assertio from a “buy” rating to a “hold” rating in a research note on Monday, March 17th. Industrial Alliance Securities set a $1.75 price target on shares of Assertio in a research report on Friday, March 14th. Finally, HC Wainwright cut their price objective on Assertio from $4.00 to $3.50 and set a “buy” rating for the company in a research report on Wednesday, March 19th.

Assertio Price Performance

NASDAQ:ASRT opened at $0.66 on Wednesday. Assertio Holdings, Inc. has a 12-month low of $0.66 and a 12-month high of $1.80. The firm has a market cap of $63.29 million, a price-to-earnings ratio of -0.91, a price-to-earnings-growth ratio of 3.25 and a beta of 0.81. The company’s 50-day moving average is $0.78 and its two-hundred day moving average is $0.92. The company has a current ratio of 2.01, a quick ratio of 1.57 and a debt-to-equity ratio of 0.30.

Assertio Profile

Assertio Holdings, Inc, a commercial pharmaceutical company, provides various products to patients in the United States. Its pharmaceutical products include INDOCIN, an oral and suppository solution for the treatment of moderate to severe rheumatoid arthritis, including acute flares of chronic disease; ankylosing spondylitis and osteoarthritis; and acute painful shoulder and gouty arthritis.